Loading...
Docoh

MyMD Pharmaceuticals (MYMD)

News

From Benzinga Pro
99 Biggest Movers From Yesterday
12 May 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company.
Stocks That Hit 52-Week Lows On Friday
6 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 1043 companies hit new 52-week lows.
MyMD Pharmaceuticals, Inc. Announces Preclinical Study Data On MYMD-1 Showing 'significantly greater anti-inflammatory effect than current TNF-alpha inhibitors on the market'
12 Apr 22
Biotech, General
MyMD seeks to disrupt the $31 billion global market for rheumatoid arthritis (RA) drug therapies with MYMD-1, which could potentially prove safer, more effective and better tolerated than current
MyMD Pharmaceuticals Accelerates Pace Of New Patient Dosing In Phase 2 Clinical Trial Of MYMD-1 As A Therapy For Delaying Aging And Extending Healthy Lifespan
5 Apr 22
News, FDA
MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced an acceleration in the pace of
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
16 Mar 22
Pre-Market Outlook, Markets, Movers
MyMD Pharmaceuticals Enrolls First Patient In Phase 2 Clinical Trial Of MYMD-1
23 Feb 22
News, FDA
MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that the first patient has

Press releases

From Benzinga Pro
MyMD Pharmaceuticals' Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis
12 Apr 22
Press Releases
MyMD seeks to disrupt the $31 billion global market for rheumatoid arthritis (RA) drug therapies with MYMD-1, which could potentially prove safer, more effective and better tolerated than current options Submission of
MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
5 Apr 22
Press Releases
28-day dosing regimen completed by several patients to date Efficacy data from fully funded Phase 2 trial is expected in first half of 2022 MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a
MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24
24 Mar 22
Press Releases
MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that Dr. Adam Kaplin, Chief Scientific Officer, will
MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
23 Feb 22
Press Releases
Efficacy data from fully funded Phase 2 trial is expected in first half of 2022 MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy